Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesCognitiveN-Acetyl-Selank

N-Acetyl-Selank

/ N-acetylated heptapeptide; Russian-origin nootropic; modified Selank for stability
SPECULATIVEN = 0 · TESTING PENDING

ALIAS · NA-Selank · Acetylated Selank · Ac-Selank

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequenceAc-TKPRPGP
MW · CLASS · N-acetylated heptapeptide; Russian-origin nootropic; modified Selank for stabilityCATEGORY · Cognitive

Tier 4. The N-acetylated form of Selank has effectively no presence in PubMed-indexed primary literature — vendor-marketed as an enhanced-stability variant of Selank without an independent published characterisation. The native (non-acetylated) Selank parent has Russian-language clinical literature; the acetylated derivative does not.

§ B · Mechanism of action

Native Selank (TKPRPGP) is a synthetic heptapeptide developed by the Institute of Molecular Genetics (Russian Academy of Sciences) as a modified analog of the immunomodulatory tetrapeptide tuftsin (TKPR), with three additional residues (PGP) intended to improve enzymatic stability. The N-acetylated derivative further blocks the free N-terminal amine to extend half-life against aminopeptidase cleavage. Mechanistic claims for the parent compound centre on GABAergic and serotonergic modulation, with reported anxiolytic effects in rodents and Russian clinical trial-like studies. Whether the acetylated derivative retains, modifies, or abolishes that activity has not been characterised in published primary literature.

§ C · Human clinical evidence

Tier 4. No PubMed-indexed primary literature on the N-acetylated derivative specifically. Inference is from the parent Selank Russian clinical and rodent literature, which is not an evidentiary substitute.

§ F · Safety signal

No formal human safety database. The parent Selank has been used clinically in Russia with reported good tolerability in Russian-language literature; safety read-across to the acetylated derivative is not supported by direct data.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

Russian-origin literature without independent Western replication — and the acetylated derivative specifically lacks even the Russian-language base of evidence that Selank itself accumulated. Vendor-marketed identity, purity, and pharmacology cannot be cross-checked against the published record.